Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
Rapid Micro Biosystems , INC. (NASDAQ:RPID), a $147 million market cap company whose stock has surged over 270% year-to-date, reported that President and CEO Robert G. Spignesi, Jr., sold a total of 33,688 shares of Class A Common Stock between July 8 and July 10, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sales were executed at prices ranging from $3.398 to $3.5127, totaling $116976. According to InvestingPro, the company maintains a strong balance sheet with more cash than debt.
The sales appear to be related to covering tax withholding obligations in connection with the vesting and settlement of performance restricted stock units.
Over the same period, Spignesi also acquired a total of 75,433 shares of Class A Common Stock as a result of the satisfaction of performance criteria underlying previously granted performance restricted stock units. These acquisitions were priced at $0.
Following these transactions, Spignesi directly owns 944015 shares of Rapid Micro Biosystems, INC.
In other recent news, Rapid Micro Biosystems reported a notable increase in first-quarter 2025 revenue, reaching $7.2 million, which exceeded the forecast of $6.6 million. Despite this revenue growth, the company’s earnings per share (EPS) came in at -$0.26, slightly below the expected -$0.24. The firm also demonstrated operational improvements, with gross margins improving from -27% to 6% and a reduction in net loss from $13.3 million to $11.3 million year-over-year. In other developments, Rapid Micro Biosystems appointed Dr. Dafni Bika to its Board of Directors. Dr. Bika, who holds a senior position at AstraZeneca (NASDAQ:AZN), is expected to contribute her extensive expertise in pharmaceutical development and manufacturing to the company’s strategic initiatives. The company also reaffirmed its full-year 2025 revenue guidance of at least $32 million, with plans to place 21-25 GrowthRx systems. Analysts from firms like Stifel and KeyBanc Capital Markets expressed interest in the company’s progress, particularly in AI integration and collaborations with MilliporeSigma. These developments underscore Rapid Micro Biosystems’ focus on enhancing its market position and operational efficiency.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.